K-means clustering to identify high risk of early revisits in patients with drug-related problems attending the emergency department.

IF 1.6 4区 医学 Q3 PHARMACOLOGY & PHARMACY European journal of hospital pharmacy : science and practice Pub Date : 2025-02-04 DOI:10.1136/ejhpharm-2024-004414
Jesus Ruiz-Ramos, Adrián Plaza-Diáz, Mireia Puig-Campmany, Caterina Sampol-Mayol, Marta Blázquez-Andión, Alicia Serrano-García-Calvo, Natalia Sanz-López, Xenia Acebes-Roldán, Ana Juanes-Borrego
{"title":"K-means clustering to identify high risk of early revisits in patients with drug-related problems attending the emergency department.","authors":"Jesus Ruiz-Ramos, Adrián Plaza-Diáz, Mireia Puig-Campmany, Caterina Sampol-Mayol, Marta Blázquez-Andión, Alicia Serrano-García-Calvo, Natalia Sanz-López, Xenia Acebes-Roldán, Ana Juanes-Borrego","doi":"10.1136/ejhpharm-2024-004414","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>Drug-related problems (DRPs) are a frequent reason for visits to the emergency department (ED). However, data about the characteristics associated with early revisits are limited. We aimed to identify clinical phenotype clusters of patients admitted to emergency rooms due DRPs to identify those patients with the highest risk of new visits.</p><p><strong>Methods: </strong>We included consecutive patients admitted to EDs due DRPs (February 2021 to December 2022), including DRP admissions in 2023 as validation cohort. We employed K-means clustering to group patients according to adjusted morbidity groups (GMA), age, and number of drugs at admission. To determine the optimal number of cluster centres, we used the elbow method. The impact of 30-day revisits in each cluster was assessed.</p><p><strong>Results: </strong>1611 patients (mean (SD) age 75.0 (15.1) years) were included. We identified six clusters, with 30-day revisits rates ranging from 14.8% to 24.5%. The main groups of drugs implicated in the DRP episodes were diuretics (190 patients; 11.8%). The most common DRP diagnoses were constipation (191; 11.9%) and gastrointestinal bleeding (158; 9.8%). Six clusters of patients were identified. Significantly higher 30-day revisits in patients identified in cluster 4 (24.5% vs 17.5%; p=0.007). The highest revisit rate was observed in the cluster including patients with a higher number of drugs and GMA status.</p><p><strong>Conclusions: </strong>Patients admitted to the ED due DRPs exhibit varying revisit rates across different clinical phenotypes. K-means clustering aids in identifying patients who derive the greatest rates of readmission, and is a useful tool to prioritise interventions in these units.</p>","PeriodicalId":12050,"journal":{"name":"European journal of hospital pharmacy : science and practice","volume":" ","pages":""},"PeriodicalIF":1.6000,"publicationDate":"2025-02-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European journal of hospital pharmacy : science and practice","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1136/ejhpharm-2024-004414","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Objective: Drug-related problems (DRPs) are a frequent reason for visits to the emergency department (ED). However, data about the characteristics associated with early revisits are limited. We aimed to identify clinical phenotype clusters of patients admitted to emergency rooms due DRPs to identify those patients with the highest risk of new visits.

Methods: We included consecutive patients admitted to EDs due DRPs (February 2021 to December 2022), including DRP admissions in 2023 as validation cohort. We employed K-means clustering to group patients according to adjusted morbidity groups (GMA), age, and number of drugs at admission. To determine the optimal number of cluster centres, we used the elbow method. The impact of 30-day revisits in each cluster was assessed.

Results: 1611 patients (mean (SD) age 75.0 (15.1) years) were included. We identified six clusters, with 30-day revisits rates ranging from 14.8% to 24.5%. The main groups of drugs implicated in the DRP episodes were diuretics (190 patients; 11.8%). The most common DRP diagnoses were constipation (191; 11.9%) and gastrointestinal bleeding (158; 9.8%). Six clusters of patients were identified. Significantly higher 30-day revisits in patients identified in cluster 4 (24.5% vs 17.5%; p=0.007). The highest revisit rate was observed in the cluster including patients with a higher number of drugs and GMA status.

Conclusions: Patients admitted to the ED due DRPs exhibit varying revisit rates across different clinical phenotypes. K-means clustering aids in identifying patients who derive the greatest rates of readmission, and is a useful tool to prioritise interventions in these units.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
K-means 聚类法识别急诊科药物相关问题患者的早期复诊高风险。
目的:药物相关问题(DRPs)是急诊科(ED)就诊的一个常见原因。然而,与早期复诊相关的特征数据却很有限。我们的目的是识别因药物相关问题而被送入急诊室的患者的临床表型群,以确定哪些患者再次就诊的风险最高:我们纳入了因 DRP 而被急诊室收治的连续患者(2021 年 2 月至 2022 年 12 月),其中包括作为验证队列的 2023 年 DRP 收治患者。我们采用 K-均值聚类方法,根据调整后的发病率组别(GMA)、年龄和入院时的药物数量对患者进行分组。为了确定最佳聚类中心数量,我们采用了肘部法。我们评估了每个群组中 30 天再次就诊的影响:共纳入 1611 名患者(平均(标清)年龄为 75.0 (15.1) 岁)。我们确定了六个群组,其 30 天复诊率从 14.8% 到 24.5% 不等。与 DRP 事件有关的主要药物类别是利尿剂(190 名患者;11.8%)。最常见的 DRP 诊断为便秘(191 例;11.9%)和消化道出血(158 例;9.8%)。共发现了六组患者。第 4 组患者的 30 天复诊率明显更高(24.5% vs 17.5%;P=0.007)。再次就诊率最高的群组包括药物数量较多且处于GMA状态的患者:结论:因DRP入院的急诊患者在不同的临床表型中表现出不同的复诊率。K均值聚类有助于识别再入院率最高的患者,是在这些科室优先采取干预措施的有用工具。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
3.40
自引率
5.90%
发文量
104
审稿时长
6-12 weeks
期刊介绍: European Journal of Hospital Pharmacy (EJHP) offers a high quality, peer-reviewed platform for the publication of practical and innovative research which aims to strengthen the profile and professional status of hospital pharmacists. EJHP is committed to being the leading journal on all aspects of hospital pharmacy, thereby advancing the science, practice and profession of hospital pharmacy. The journal aims to become a major source for education and inspiration to improve practice and the standard of patient care in hospitals and related institutions worldwide. EJHP is the only official journal of the European Association of Hospital Pharmacists.
期刊最新文献
Advancing global hospital pharmacy: the enduring impact and call to action of the FIP Basel Statements. Resolution rate of prescribing errors after advice from a specialised hospital pharmacist or a substitute hospital pharmacist: a retrospective cross-sectional study. Evaluation of statin-induced muscle and liver adverse drug reactions in the Chinese population: a retrospective analysis of clinical trial data from 1992 to 2023. Colchicine-enzalutamide interaction: clinical implications and multi-disciplinary management. Managing refractory cytomegalovirus in an immunosuppressed patient with sarcoidosis: a case report on maribavir therapy.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1